Aviva PLC reduced its position in MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) by 35.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 65,346 shares of the company's stock after selling 36,633 shares during the period. Aviva PLC's holdings in MiMedx Group were worth $629,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently modified their holdings of MDXG. Trexquant Investment LP increased its position in MiMedx Group by 29.7% during the 4th quarter. Trexquant Investment LP now owns 221,262 shares of the company's stock valued at $2,129,000 after buying an additional 50,635 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of MiMedx Group by 22.8% during the fourth quarter. Wellington Management Group LLP now owns 389,706 shares of the company's stock worth $3,749,000 after acquiring an additional 72,432 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in shares of MiMedx Group by 484.2% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 362,481 shares of the company's stock valued at $3,487,000 after acquiring an additional 300,433 shares in the last quarter. Norges Bank purchased a new position in shares of MiMedx Group in the 4th quarter valued at approximately $4,020,000. Finally, JPMorgan Chase & Co. boosted its stake in MiMedx Group by 133.1% in the 4th quarter. JPMorgan Chase & Co. now owns 693,106 shares of the company's stock worth $6,668,000 after purchasing an additional 395,739 shares in the last quarter. Hedge funds and other institutional investors own 79.15% of the company's stock.
MiMedx Group Stock Performance
MDXG traded down $0.10 during trading on Tuesday, reaching $6.67. 236,471 shares of the company's stock were exchanged, compared to its average volume of 694,489. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53. MiMedx Group, Inc. has a 1 year low of $5.47 and a 1 year high of $10.14. The company's fifty day simple moving average is $7.82 and its 200-day simple moving average is $8.01. The stock has a market capitalization of $982.93 million, a P/E ratio of 12.13 and a beta of 1.74.
MiMedx Group (NASDAQ:MDXG - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.07. The company had revenue of $92.91 million during the quarter, compared to the consensus estimate of $89.42 million. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. As a group, research analysts predict that MiMedx Group, Inc. will post 0.3 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of research firms have issued reports on MDXG. StockNews.com raised shares of MiMedx Group from a "buy" rating to a "strong-buy" rating in a report on Friday, April 4th. Cantor Fitzgerald restated an "overweight" rating and issued a $13.00 target price on shares of MiMedx Group in a research note on Thursday, February 27th.
Check Out Our Latest Stock Report on MiMedx Group
Insider Transactions at MiMedx Group
In other MiMedx Group news, CAO William Frank Iv Hulse sold 81,446 shares of MiMedx Group stock in a transaction on Monday, March 10th. The shares were sold at an average price of $7.80, for a total value of $635,278.80. Following the completion of the transaction, the chief accounting officer now owns 494,774 shares of the company's stock, valued at approximately $3,859,237.20. The trade was a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Kimberly Maersk-Moller sold 4,106 shares of the firm's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $7.89, for a total value of $32,396.34. Following the sale, the insider now owns 310,836 shares in the company, valued at $2,452,496.04. This trade represents a 1.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 144,018 shares of company stock worth $1,130,312 over the last quarter. 1.30% of the stock is currently owned by insiders.
MiMedx Group Profile
(
Free Report)
MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.
Read More
Before you consider MiMedx Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiMedx Group wasn't on the list.
While MiMedx Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
